We are live on ! Find out more
BIOTW

Biotech Acquisition Company Warrant
BIOTW

Delisted

BIOTW was delisted on the 2nd of February, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in Biotech Acquisition Company Warrant in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 47 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 48 → 0 (-48)

100% less capital invested

Capital invested by funds: $3.83M → $0 (-$3.83M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 47

Holders
–
Holders Change
-48
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
47
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
RCM
Radcliffe Capital Management
Pennsylvania
-$2.05M
2
BFM
Boothbay Fund Management
New York
-$611K
3
LP
LMR Partners
United Kingdom
-$505K
4
SCM
Segantii Capital Management
Hong Kong
-$252K
5
HIM
HGC Investment Management
Ontario, Canada
-$78K
Name Holding Trade Value Shares
Change 		Change in
Stake
CCA
26
Castle Creek Arbitrage
Colorado
– -$3.11K -50,000 Closed
CP
27
Centerbridge Partners
New York
– -$3.19K -50,000 Closed
LP
28
LMR Partners
United Kingdom
– -$505K -50,000 Closed
CCM
29
Context Capital Management
California
– -$3K -47,200 Closed
CS
30
Clear Street
New York
– -$3K -45,861 Closed
Walleye Trading
31
Walleye Trading
New York
– -$2.56K -40,000 Closed
State of Wisconsin Investment Board
32
State of Wisconsin Investment Board
Wisconsin
– -$2.4K -37,500 Closed
Citadel Advisors
33
Citadel Advisors
Florida
– -$2.28K -35,706 Closed
WAM
34
Wolverine Asset Management
Illinois
– -$2.24K -35,056 Closed
SSA
35
Schonfeld Strategic Advisors
New York
– -$1.92K -30,000 Closed
PFM
36
Privium Fund Management
Netherlands
– -$1.27K -28,004 Closed
AA
37
AQR Arbitrage
Connecticut
– -$1.69K -26,499 Closed
MC
38
Meteora Capital
Florida
– -$1.6K -25,000 Closed
SCM
39
Segantii Capital Management
Hong Kong
– -$252K -25,000 Closed
CC
40
Centiva Capital
New York
– -$989 -16,483 Closed
AA
41
Ancora Advisors
Ohio
– -$1K -15,350 Closed
BCM
42
BCK Capital Management
Connecticut
– -$867 -13,573 Closed
OAC
43
OMERS Administration Corp
Ontario, Canada
– -$799 -12,500 Closed
Susquehanna International Group
44
Susquehanna International Group
Pennsylvania
– -$660 -10,328 Closed
Bank of America
45
Bank of America
North Carolina
– -$634 -10,063 Closed
UBS Group
46
UBS Group
Switzerland
– -$4 -59 Closed
1
2

BIOTW Hedge Fund Activity: Q1 2023 in Review

0 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Warrant (BIOTW) for Q1 2023, worth a combined $0 — down 100% from $3.83M a quarter earlier.

Sellers outnumbered buyers: 47 funds closed out of BIOTW and 0 opened new positions — a net loss of 47 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Radcliffe Capital Management, exiting entirely with an estimated $2.05M sold.

  • 0 institutional investors held Biotech Acquisition Company Warrant (BIOTW) as of Q1 2023, down from 48 in Q4 2022.
  • Funds reported $0 of Biotech Acquisition Company Warrant stock for Q1 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Biotech Acquisition Company Warrant positions in Q1 2023 and 47 closed out, a net change of -47 holders.
  • The largest Biotech Acquisition Company Warrant seller in Q1 2023 was Radcliffe Capital Management, an estimated $2.05M sold.

Based on aggregated 13F filings for Q1 2023.